RIPK1-IN-19 is a small molecule inhibitor specifically designed to target receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in regulating cell death and inflammation pathways. This compound is part of a broader class of inhibitors that aim to modulate necroptosis, a form of programmed cell death, and has potential therapeutic applications in various diseases, including neurodegenerative disorders and inflammatory conditions. The chemical structure of RIPK1-IN-19 typically features specific functional groups that enhance its binding affinity to the RIPK1 enzyme, thereby inhibiting its activity. The compound is characterized by its ability to selectively inhibit RIPK1 without significantly affecting other kinases, which is essential for minimizing off-target effects. Additionally, studies have indicated that RIPK1-IN-19 may exhibit favorable pharmacokinetic properties, making it a candidate for further development in preclinical and clinical settings. As with any investigational compound, ongoing research is necessary to fully elucidate its efficacy, safety profile, and potential applications in therapeutic contexts.

RIPK1-IN-19

2763831-43-0: RIPK1-IN-19 is a small molecule inhibitor specifically designed to target receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in regulating cell death and inflammation pathways. This compound is part of a broader class of inhibitors that aim to modulate necroptosis, a form of programmed cell death, and has potential therapeutic applications in various diseases, including neurodegenerative disorders and inflammatory conditions. The chemical structure of RIPK1-IN-19 typically features specific functional groups that enhance its binding affinity to the RIPK1 enzyme, thereby inhibiting its activity. The compound is characterized by its ability to selectively inhibit RIPK1 without significantly affecting other kinases, which is essential for minimizing off-target effects. Additionally, studies have indicated that RIPK1-IN-19 may exhibit favorable pharmacokinetic properties, making it a candidate for further development in preclinical and clinical settings. As with any investigational compound, ongoing research is necessary to fully elucidate its efficacy, safety profile, and potential applications in therapeutic contexts.

<p>RIPK1-IN-19 is a selective and potent RIPK1 inhibitor that protects against cell necrosis in the tnf α-induced SIRS model and IMQ-induced psoriasis model.</p>

CAS 2763831-43-0

RIPK1-IN-19

RIPK1-IN-19

Ref: TM-T87334